A phase III study comparing Vectibix (panitumumab) and best supportive care met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer.

This is the first phase III Vectibix study to include an analysis of efficacy of Vectibix by wild-type KRAS (exon 2) and in wild-type RAS tumor mutation status in its primary analysis, according to Amgen, the drug’s sponsor.

The study results, in addition to secondary endpoint data, were presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco.